There is a little known company that is changing warfare

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

Louis Petrillo Biography and Net Worth

Insider of Fate Therapeutics

Louis Petrillo is the Insider of Fate Therapeutics.

What is Louis T. Petrillo's net worth?: The estimated net worth of Louis T. Petrillo is at least $212,613.08 as of May 10th, 2023. Petrillo owns 105,254 shares of Fate Therapeutics stock worth more than $212,613 as of November 17th. This net worth approximation does not reflect any other investments that Petrillo may own. Learn More about Louis T. Petrillo's net worth.
How do I contact Louis T. Petrillo?: The corporate mailing address for Petrillo and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]. Learn More on Louis T. Petrillo's contact information.
Has Louis T. Petrillo been buying or selling shares of Fate Therapeutics?: Louis T. Petrillo has not been actively trading shares of Fate Therapeutics over the course of the past ninety days. Learn More on Louis T. Petrillo's trading history.
Who are Fate Therapeutics' active insiders?: Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.
Are insiders buying or selling shares of Fate Therapeutics?: In the last year, Fate Therapeutics insiders bought shares 1 times. They purchased a total of 44,630 shares worth more than $166,023.60. In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 46,046 shares worth more than $202,409.98. The most recent insider tranaction occured on August, 6th when Director Yuan Xu sold 633 shares worth more than $2,677.59. Insiders at Fate Therapeutics own 5.0% of the company. Learn More about insider trades at Fate Therapeutics.
Information on this page was last updated on 8/6/2024.

Louis T. Petrillo Insider Trading History at Fate Therapeutics

Louis T. Petrillo Buying and Selling Activity at Fate Therapeutics

Fate Therapeutics Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $2.02

$1.96

$2.12

50 Day Range

MA: $3.11

$2.02

$4.02

2 Week Range

Now: $2.02

$1.96

$8.83

Volume

1,752,594 shs

Average Volume

1,503,266 shs

Market Capitalization

$230.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88